Want to see HK:2561 full AI Analyst Report?
2561 Stock Chart & Stats
HK$33.68
--
Market closed
HK$33.68
--
Day’s Range― - ―
52-Week RangeHK$18.88 - HK$52.90
Previous CloseN/A
VolumeN/A
Average Volume (3M)37.57K
Market Cap
HK$2.28B
Enterprise ValueHK$1.39B
Total Cash (Recent Filing)HK$805.91M
Total Debt (Recent Filing)HK$1.20M
Price to Earnings (P/E)―
Beta0.93
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding113,926,865
10 Day Avg. Volume36,930
30 Day Avg. Volume37,566
Financial Highlights & Ratios
PEG Ratio-0.56
Price to Book (P/B)4.01
Price to Sales (P/S)19001.90
P/FCF Ratio-6.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Relatively Strong Balance SheetLow-to-moderate leverage provides a structural buffer versus peers: it reduces near-term refinancing risk and preserves optionality for funding R&D or trials. This balance-sheet strength lengthens runway and supports strategic initiatives even while operations remain loss-making.
Positive Gross ProfitSustained positive gross profit indicates the company’s core products or pipelines can generate unit-level economics. If operating expenses are reined in or revenues stabilize, this structural margin at the gross level enables a path to profitability and scalable operating leverage over time.
Industry: Specialty & Generic DrugsOperating in specialty and generic pharmaceuticals exposes the company to durable demand and niche pricing dynamics. Structural healthcare needs and product differentiation in specialty areas can sustain long-term revenue opportunities and reduce cyclicality versus commodity sectors.
Bears Say
Persistent Large LossesOngoing large net losses materially weaken retained earnings and shareholders' returns. Prolonged unprofitability constrains capacity to self-finance growth, forces reliance on dilutive funding or debt, and raises structural risk if cost or revenue trajectories do not improve.
Negative And Worsening Cash FlowConsistently negative operating and free cash flow increases dependence on external financing and heightens refinancing risk. Worsening cash burn in 2025 reduces runway, constrains investment choices, and can force strategic trade-offs that impair long-term competitiveness.
Revenue Decline And Weak PerformanceA sharp revenue drop undermines operating leverage and suggests weakening market traction or execution issues. Declining sales combined with high operating costs make recovery to sustainable profitability more difficult and raise the probability that additional capital will be required.
VISEN Pharmaceuticals News
2561 FAQ
What was VISEN Pharmaceuticals’s price range in the past 12 months?
VISEN Pharmaceuticals lowest stock price was HK$18.88 and its highest was HK$52.90 in the past 12 months.
What is VISEN Pharmaceuticals’s market cap?
VISEN Pharmaceuticals’s market cap is HK$2.28B.
When is VISEN Pharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were VISEN Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is VISEN Pharmaceuticals overvalued?
According to Wall Street analysts VISEN Pharmaceuticals’s price is currently Overvalued.
Does VISEN Pharmaceuticals pay dividends?
VISEN Pharmaceuticals does not currently pay dividends.
What is VISEN Pharmaceuticals’s EPS estimate?
VISEN Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does VISEN Pharmaceuticals have?
VISEN Pharmaceuticals has 113,926,865 shares outstanding.
What happened to VISEN Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of VISEN Pharmaceuticals?
Currently, no hedge funds are holding shares in HK:2561
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
VISEN Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Company Description
VISEN Pharmaceuticals
VISEN Pharmaceuticals operates as an investment holding company, concentrating on the development and commercialization of endocrine treatments across mainland China, Hong Kong, and Taiwan. Their flagship product, Lonapegsomatropin, offers a once-weekly, long-acting growth hormone replacement designed for pediatric growth hormone deficiency. The company is also progressing other therapies, such as TransCon CNP (navepegritide), a long-acting prodrug utilizing c-type natriuretic peptide for achondroplasia, and Palopegteriparatide, a daily parathyroid hormone replacement therapy intended for chronic hypoparathyroidism. VISEN has forged strategic collaborations with Shanghai Pharmaceutical and United Family Healthcare. The enterprise was founded in 2018 and is based in Suzhou, China.
Technical Analysis
HUTCHMED (China)
―
Hua Medicine
―
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
―
Hansoh Pharmaceutical Group Company Limited
―
CanSino Biologics, Inc. Class H
―